The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms
Abstract
CD74 is an integral membrane protein that functions as a MHC class II chaperone. Moreover, it has recently been shown to have a role as an accessory-signaling molecule and has been implicated in malignant B-cell proliferation and survival. These biological functions combined with expression of CD74 on malignant B cells and limited expression on normal tissues implicate CD74 as a potential therapeutic target. The anti-CD74 monoclonal antibody LL1 has been humanized (hLL1 milatuzumab or IMMU-115) and can provide the basis for novel therapeutic approaches to B-cell malignancies, particularly because this antibody shows rapid internalization into CD74+ malignant cells. This article reviews the preclinical evaluations of LL1, its humanized form, and isotope, drug, and toxin conjugates. These studies show that unconjugated hLL1 and conjugates of hLL1 constructs with radioisotopes, doxorubicin, and frog RNase have high antitumor activity in non–Hodgkin's lymphoma and multiple myeloma in vitro and in tumor xenograft models. Single-dose studies of hLL1 in monkeys showed no adverse effects but did decrease circulating B and T lymphocytes and natural killer cells. When evaluated in combination with rituximab, either equivalent or improved efficacy, compared with either antibody alone, was observed. CD74 is a new candidate target for the immunotherapy of neoplasms expressing this antigen, which can be exploited using either a naked antibody or conjugated to isotopes, drugs, or toxins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649
Roger, T., Chanson, A., Knaup‐Reymond, M., & Calandra, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200535413 · Cited by 184
CD74 Is a Member of the Regulated Intramembrane Proteolysis-processed Protein Family
Becker-Herman, S., Arie, G., Medvedovsky, H., Kerem, A., & Shachar, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-04-0327 · Cited by 141
Cited by
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension
Rabinovitch, M., Guignabert, C., Humbert, M., & Nicolls, M. R. (2014) · Circulation Research · doi:10.1161/circresaha.113.301141 · Cited by 1,029
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Sumaiya, K., Langford, D., Natarajaseenivasan, K., & Shanmughapriya, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108024 · Cited by 299
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
The multifaceted roles of the invariant chain CD74 — More than just a chaperone
Schröder, B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.026 · Cited by 284
Metadata
- Authors
- Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C.-H., Burton, J., Govindan, S., & Goldenberg, D. M.
- Venue
- Clinical Cancer Research
- Published
- 2007-09-15
- Volume
- 13
- Issue
- 18
- Pages
- 5556s-5563s
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2168267840
- Cited by
- 228
- References
- 3
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1167
- The paper
- Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C.-H., Burton, J., Govindan, S., & Goldenberg, D. M. (2007). CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.